Lin Xu

4.6k total citations · 1 hit paper
143 papers, 2.6k citations indexed

About

Lin Xu is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Cancer Research. According to data from OpenAlex, Lin Xu has authored 143 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Molecular Biology, 23 papers in Cardiology and Cardiovascular Medicine and 21 papers in Cancer Research. Recurrent topics in Lin Xu's work include CRISPR and Genetic Engineering (11 papers), Sarcoma Diagnosis and Treatment (11 papers) and Cardiac electrophysiology and arrhythmias (10 papers). Lin Xu is often cited by papers focused on CRISPR and Genetic Engineering (11 papers), Sarcoma Diagnosis and Treatment (11 papers) and Cardiac electrophysiology and arrhythmias (10 papers). Lin Xu collaborates with scholars based in United States, China and Hong Kong. Lin Xu's co-authors include Eric N. Olson, Rhonda Bassel‐Duby, Ning Liu, Kenian Chen, Wei Tan, Hui Li, Miao Cui, Xue Xiao, John McAnally and Jian‐xing Ma and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Lin Xu

135 papers receiving 2.6k citations

Hit Papers

Base editing correction of hypertrophic cardiomyopathy in... 2023 2026 2024 2025 2023 25 50 75 100

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lin Xu United States 29 1.7k 472 410 299 295 143 2.6k
Ingeborg Hers United Kingdom 28 1.9k 1.1× 450 1.0× 338 0.8× 260 0.9× 411 1.4× 65 3.6k
Hongqiang Cheng China 31 1.9k 1.1× 884 1.9× 459 1.1× 272 0.9× 217 0.7× 77 2.8k
Vincent Sauzeau France 27 1.8k 1.1× 509 1.1× 336 0.8× 358 1.2× 238 0.8× 51 3.3k
Chenghui Yan China 27 1.2k 0.7× 363 0.8× 360 0.9× 138 0.5× 403 1.4× 166 2.3k
Jianxin Sun United States 33 1.8k 1.0× 374 0.8× 767 1.9× 266 0.9× 680 2.3× 75 3.5k
Stefan Günther Germany 23 1.3k 0.8× 221 0.5× 231 0.6× 317 1.1× 233 0.8× 52 2.0k
Saptarsi M. Haldar United States 30 2.3k 1.3× 669 1.4× 293 0.7× 144 0.5× 344 1.2× 54 3.6k
Xiaojun Zhu China 25 1.9k 1.1× 258 0.5× 253 0.6× 136 0.5× 292 1.0× 58 2.5k
Lars Muhl Sweden 21 1.1k 0.6× 248 0.5× 259 0.6× 191 0.6× 311 1.1× 38 2.3k
Pascal Bernatchez Canada 30 1.7k 1.0× 552 1.2× 298 0.7× 315 1.1× 304 1.0× 78 3.0k

Countries citing papers authored by Lin Xu

Since Specialization
Citations

This map shows the geographic impact of Lin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Xu more than expected).

Fields of papers citing papers by Lin Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Xu. The network helps show where Lin Xu may publish in the future.

Co-authorship network of co-authors of Lin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Xu. A scholar is included among the top collaborators of Lin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Xu. Lin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Kenian, et al.. (2025). Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor. Cell Reports Medicine. 6(5). 102133–102133.
2.
Lin, Chang‐Ching, Nisha Unni, Yisheng Fang, et al.. (2025). ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 31(9). 1667–1675. 2 indexed citations
4.
Desai, Kavita, Jiwoong Kim, Qinbo Zhou, et al.. (2024). DROSHA Regulates Mesenchymal Gene Expression in Wilms Tumor. Molecular Cancer Research. 22(8). 711–720. 2 indexed citations
5.
Tang, Chen, Ruichen Rong, Ying Ma, et al.. (2024). BayeSMART: Bayesian clustering of multi-sample spatially resolved transcriptomics data. Briefings in Bioinformatics. 25(6). 1 indexed citations
6.
Gan, Peiheng, Heankel Lyons, Akansha M. Shah, et al.. (2024). Coactivator condensation drives cardiovascular cell lineage specification. Science Advances. 10(11). eadk7160–eadk7160. 11 indexed citations
7.
Wu, Junyu, Yau-Tuen Chan, Yuanjun Lu, et al.. (2023). Genipin-activating PPARγ impedes CCR2-mediated macrophage infiltration into postoperative liver to suppress recurrence of hepatocellular carcinoma. International Journal of Biological Sciences. 19(16). 5257–5274. 6 indexed citations
8.
Zhang, Yichi, Andres Ramirez-Martinez, Kenian Chen, et al.. (2023). Net39 protects muscle nuclei from mechanical stress during the pathogenesis of Emery-Dreifuss muscular dystrophy. Journal of Clinical Investigation. 133(13). 4 indexed citations
9.
Lebek, Simon, Xurde M. Caravia, Leon G. Straub, et al.. (2023). CRISPR-Cas9 base editing of pathogenic CaMKIIδ improves cardiac function in a humanized mouse model. Journal of Clinical Investigation. 134(1). 20 indexed citations
10.
Lebek, Simon, Francesco Chemello, Xurde M. Caravia, et al.. (2023). Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science. 379(6628). 179–185. 73 indexed citations
11.
Liu, Yen‐Ting, Xue Xiao, Lei Guo, et al.. (2023). Methyltransferase Inhibition Enables Tgfβ Driven Induction of CDKN2A and B in Cancer Cells. Molecular and Cellular Biology. 43(3). 115–129. 1 indexed citations
12.
Santos, Matthieu Dos, Akansha M. Shah, Yichi Zhang, et al.. (2023). Opposing gene regulatory programs governing myofiber development and maturation revealed at single nucleus resolution. Nature Communications. 14(1). 4333–4333. 25 indexed citations
13.
Shah, Akansha M., Lei Guo, María Gabriela Morales, et al.. (2023). TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma. Science Advances. 9(17). eade8184–eade8184. 10 indexed citations
14.
Nishiyama, Takahiko, Yu Zhang, Miao Cui, et al.. (2022). Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Science Translational Medicine. 14(672). eade1633–eade1633. 103 indexed citations
15.
Yao, Huiyu, Yue Ma, Yuannyu Zhang, et al.. (2022). Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm. Blood. 140(22). 2371–2384. 8 indexed citations
16.
Rong, Ruichen, Shuang Jiang, Lin Xu, et al.. (2021). MB-GAN: Microbiome Simulation via Generative Adversarial Network. GigaScience. 10(2). 22 indexed citations
17.
Lu, Tianshi, Shidan Wang, Lin Xu, et al.. (2020). Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology. 5(44). 30 indexed citations
18.
Liu, Yen‐Ting, Lin Xu, Lynda Bennett, et al.. (2019). Identification of De Novo Enhancers Activated by TGFβ to Drive Expression of CDKN2A and B in HeLa Cells. Molecular Cancer Research. 17(9). 1854–1866. 4 indexed citations
19.
Zheng, Yanbin, Lin Xu, Mohammed Hassan, et al.. (2019). Bayesian Modeling Identifies PLAG1 as a Key Regulator of Proliferation and Survival in Rhabdomyosarcoma Cells. Molecular Cancer Research. 18(3). 364–374. 13 indexed citations
20.
Laetsch, Theodore W., Angshumoy Roy, Lin Xu, et al.. (2018). Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group. Clinical Cancer Research. 24(16). 3888–3897. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026